Analysts’ Top Healthcare Picks: GKOS, GLPG

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Glaukos (NYSE: GKOS), Galapagos NV (NASDAQ: GLPG) and Alexion Pharmaceuticals (NASDAQ: ALXN) with bullish sentiments.

Glaukos (NYSE: GKOS)

In a report released today, Jonathan Block from Stifel Nicolaus reiterated a Buy rating on Glaukos (NYSE: GKOS), with a price target of $55. The company’s shares opened today at $33.84.

According to TipRanks.com, Block is a 5-star analyst with an average return of 20.0% and a 74.6% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Zeltiq Aesthetics.

Currently, the analyst consensus on Glaukos is Strong Buy and the average price target is $55.80, representing a 64.9% upside.

In a report issued on August 31, BMO Capital also reiterated a Buy rating on the stock with a $54 price target.
Galapagos NV (NASDAQ: GLPG)

In a report released today, Adam Walsh from Stifel Nicolaus reiterated a Buy rating on Galapagos NV (NASDAQ: GLPG), with a price target of $120. The company’s shares opened today at $103.47, close to its 52-week high of $103.54.

According to TipRanks.com, Walsh is a 4-star analyst with an average return of 16.0% and a 49.2% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Vertex Pharmaceuticals, and Reata Pharmaceuticals.

Galapagos NV has an analyst consensus of Strong Buy, with a price target consensus of $107.67.

Alexion Pharmaceuticals (NASDAQ: ALXN)

Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) on September 12 and set a price target of $165. The company’s shares opened today at $144.61, close to its 52-week high of $149.34.

According to TipRanks.com, Willey is a 5-star analyst with an average return of 23.6% and a 56.1% success rate. Willey covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Applied Genetic Technologies, and Hutchison China MediTech Ltd.

Currently, the analyst consensus on Alexion Pharmaceuticals is Strong Buy and the average price target is $162.42, representing a 12.3% upside.

In a report issued on September 5, J.P. Morgan also upgraded the stock to Buy with a $175 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.